NASDAQ:MGNX - MacroGenics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $22.39 +0.12 (+0.54 %) (As of 07/23/2018 09:45 AM ET)Previous Close$22.27Today's Range$22.17 - $22.3952-Week Range$14.36 - $32.74Volume1,694 shsAverage Volume211,097 shsMarket Capitalization$939.84 millionP/E Ratio-41.46Dividend YieldN/ABeta2.46 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It is also developing Flotetuzumab, a DART molecule that targets CD123 and CD3; MGA012, a monoclonal antibody, which targets programmed cell death protein 1 (PD-1); MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; MGD019, a preclinical DART molecule designed to recognize the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company develops MGD009, a DART molecule recognizes B7-H3 and CD3; MGC018, a B7-H3 antibody-drug conjugate; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Teplizumab, an anti-CD3 monoclonal antibody to treat type 1 diabetes; MGD010, a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells; and MGD014, a DART molecule that targets the envelope protein of human immunodeficiency virus, or HIV-infected cells and CD3-expressing T cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland. Receive MGNX News and Ratings via Email Sign-up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:MGNX CUSIPN/A Webwww.macrogenics.com Phone301-251-5172 Debt Debt-to-Equity RatioN/A Current Ratio5.43 Quick Ratio5.43 Price-To-Earnings Trailing P/E Ratio-41.46 Forward P/E Ratio-4.72 P/E GrowthN/A Sales & Book Value Annual Sales$157.74 million Price / Sales5.99 Cash FlowN/A Price / CashN/A Book Value$8.13 per share Price / Book2.75 Profitability EPS (Most Recent Fiscal Year)($0.54) Net Income$-19,620,000.00 Net Margins-19.64% Return on Equity-13.03% Return on Assets-10.36% Miscellaneous Employees330 Outstanding Shares42,200,000Market Cap$939.84 MacroGenics (NASDAQ:MGNX) Frequently Asked Questions What is MacroGenics' stock symbol? MacroGenics trades on the NASDAQ under the ticker symbol "MGNX." How were MacroGenics' earnings last quarter? MacroGenics Inc (NASDAQ:MGNX) announced its quarterly earnings results on Monday, May, 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.08) by $0.26. The biopharmaceutical company had revenue of $4.70 million for the quarter, compared to analyst estimates of $7.46 million. MacroGenics had a negative net margin of 19.64% and a negative return on equity of 13.03%. View MacroGenics' Earnings History. What price target have analysts set for MGNX? 11 equities research analysts have issued 1 year price targets for MacroGenics' shares. Their forecasts range from $22.00 to $44.00. On average, they expect MacroGenics' stock price to reach $31.50 in the next twelve months. This suggests a possible upside of 41.4% from the stock's current price. View Analyst Ratings for MacroGenics. What is the consensus analysts' recommendation for MacroGenics? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about MacroGenics stock? Here are some recent quotes from research analysts about MacroGenics stock: 1. According to Zacks Investment Research, "MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. " (7/18/2018) 2. HC Wainwright analysts commented, "We are currently not valuing the B7-H3 franchise pending clinical updates on the combination program with Keytruda and preliminary read from the B7-H3 x CD3 DART molecule, which if positive could rival the remainder of the pipeline in terms of clinical importance. Risks potentially incurred investing in this stock include: clinical and development, financial, regulatory and reimbursement, and commercial." (6/4/2018) Who are some of MacroGenics' key competitors? Some companies that are related to MacroGenics include Array Biopharma (ARRY), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), Evotec (EVTCY), The Medicines (MDCO), Horizon Pharma (HZNP), Ascendis Pharma A/S (ASND), Supernus Pharmaceuticals (SUPN), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), Blueprint Medicines (BPMC), Emergent Biosolutions (EBS), Akcea Therapeutics (AKCA) and Portola Pharmaceuticals (PTLA). Who are MacroGenics' key executives? MacroGenics' management team includes the folowing people: Dr. Scott Koenig, CEO, Pres & Director (Age 66)Mr. James Karrels, Sr. VP, CFO & Sec. (Age 51)Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 64)Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 45)Dr. Jon M. Wigginton, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 56) Has MacroGenics been receiving favorable news coverage? News stories about MGNX stock have been trending somewhat positive this week, Accern reports. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. MacroGenics earned a media sentiment score of 0.04 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 46.04 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. Who are MacroGenics' major shareholders? MacroGenics' stock is owned by many different of institutional and retail investors. Top institutional investors include Fox Run Management L.L.C. (0.04%). Company insiders that own MacroGenics stock include Eric Blasius Risser, James Karrels, Jon Marc Wigginton and Lynn Cilinski. View Institutional Ownership Trends for MacroGenics. Which institutional investors are buying MacroGenics stock? MGNX stock was purchased by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C.. View Insider Buying and Selling for MacroGenics. How do I buy shares of MacroGenics? Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is MacroGenics' stock price today? One share of MGNX stock can currently be purchased for approximately $22.27. How big of a company is MacroGenics? MacroGenics has a market capitalization of $939.84 million and generates $157.74 million in revenue each year. The biopharmaceutical company earns $-19,620,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. MacroGenics employs 330 workers across the globe. How can I contact MacroGenics? MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172. MarketBeat Community Rating for MacroGenics (NASDAQ MGNX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 227 (Vote Outperform)Underperform Votes: 225 (Vote Underperform)Total Votes: 452MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe MGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGNX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/23/2018 by MarketBeat.com StaffFeatured Article: What does earnings per share mean?